Pakistan is on the verge of introducing Bulevirtide, a first-of-its-kind therapy designed to treat Hepatitis Delta (HDV), potentially altering the prognosis for thousands of patients across the country.
Health officials and local pharmaceutical representatives have confirmed that regulatory discussions are in the final stages. If approved, this will mark the first time a targeted entry inhibitor—which prevents the virus from entering liver cells—becomes accessible within the national healthcare framework.
The stakes are high. Hepatitis Delta is the most severe form of viral hepatitis, often accelerating liver cirrhosis and increasing the risk of hepatocellular carcinoma far faster than Hepatitis B or C alone. For decades, clinicians in Pakistan have relied on off-label interferon treatments, which carry heavy side effects and offer limited success rates.
“We are looking at a clinical shift,” said a senior hepatologist involved in the preliminary local trials. “Interferon was a blunt instrument. Bulevirtide acts as a shield for the liver. It changes the entire conversation for patients who were previously told they had few options.”
Despite the clinical optimism, the primary hurdle remains pricing and accessibility. Bulevirtide is expensive by international standards, and bringing it into a market where public health budgets are stretched requires a delicate balance.
Negotiations are currently focused on a tiered pricing model. The government is pushing for a localized manufacturing agreement or a significant subsidy, aiming to make the therapy affordable for patients in both public sector hospitals and private clinics.
“The goal isn’t just to authorize the drug,” a source at the Drug Regulatory Authority of Pakistan (DRAP) said. “The goal is to ensure that a patient in a rural district has the same access as one in a major metropolitan center. We won’t sign off on a rollout that only serves the elite.”
The introduction of this therapy follows a period of intense pressure on the health ministry to modernize its approach to chronic liver disease, which remains a leading cause of mortality in the country. With the regulatory framework now being finalized, authorities expect to announce a formal timeline for distribution by the end of the next quarter.
If the rollout succeeds, it could set a precedent for how Pakistan approaches the acquisition of specialized, high-cost medications for other rare or severe diseases. For now, the focus is on the final bureaucratic hurdles—and the hope that a long-awaited solution for HDV patients is finally within reach.
